Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02052011 · ClinicalTrials.gov registry record · Phase 4
Ranolazine and Microvascular Angina by PET in the Emergency Department
A Phase 4 study of Microvascular Angina, sponsored by Yale University.
- Completed
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT02052011 is a Phase 4 study of Microvascular Angina that has completed, run by Yale University. The registered enrollment target is 31 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02052011, a Phase 4 study of Microvascular Angina, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effectiveness of Ranolazine for the treatment chest pain from disease of small vessels of the heart also known as 'microvascular angina'.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ranolazine
Study Locations (1)
Connecticut
- Yale New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02052011
The ClinicalTrials.gov registry entry for NCT02052011 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Microvascular Angina appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02052011 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT02052011 about?
NCT02052011 is a clinical study titled "Ranolazine and Microvascular Angina by PET in the Emergency Department". The purpose of this study is to determine the effectiveness of Ranolazine for the treatment chest pain from disease of small vessels of the heart also known as 'microvascular angina'.
What is the current status of trial NCT02052011?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2014-04. Estimated completion is 2015-11.
What conditions does trial NCT02052011 study?
This clinical trial studies the following conditions: Microvascular Angina.
What interventions are being tested in trial NCT02052011?
The interventions under investigation include: Placebo (DRUG), Ranolazine (DRUG).
Who is sponsoring clinical trial NCT02052011?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02052011 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Microvascular Angina
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.